Last updated on April 23, 2014 at 21:24 EDT

Groundbreaking Chemistry Research Recognized Through the Reaxys® PhD Competition

December 15, 2011

NEUCHATEL, Switzerland, December 15, 2011 /PRNewswire/ –

               3rd Annual Reaxys(R) PhD Prize launched to award original and innovative
                   research in organic, organometallic and inorganic chemistry

Reaxys(R), a leading workflow solution that provides extensive information on chemical
compounds, related physical and pharmacological properties, today announced the launch of
the 3rd Annual Reaxys(R) PhD Prize. The competition is for Chemistry students currently
studying for a PhD or having completed a PhD within the last 12 months.

The prize will be awarded to the candidates that best demonstrate excellence in
methodology and approach in a peer-reviewed publication. Three prize winners will each
receive a check for $2000 and will be invited to present their research at the Winners’

The 2012 Winners’ Symposium will be held at the American Chemical Society (ACS) Fall
Meeting in Philadelphia, August 19- 23, 2012. The Symposium is sponsored by the ACS
Division of Inorganic Chemistry and co-sponsored by the ACS Division of Organic Chemistry.
The three winners will each present their papers at the symposium alongside presentations
given by two members of the Reaxys(R) Advisory Board – Professor Barry M. Trost (Stanford
University) and Professor Dr Martin Jansen (Max Planck Institute, Stuttgart).

“After two successful years, the Reaxys(R) PhD Prize is already establishing itself as
the premier international prize for PhD Chemists,” said David Evans PhD, Scientific
Affairs Director at Elsevier Properties SA. “Prior winners and finalists represent the
best cutting edge chemistry research being performed by young chemists at some of the
world’s top universities. We are excited to see how well this year’s candidates will
measure up in terms of research excellence, rigor and innovation – qualities to which the
whole Reaxys(R) team is also committed to achieve.”

All entries will be reviewed by a review board of leading international chemists,
chaired by the following members of the Reaxys(R) Advisory Board:

        - Professor A. G. M. Barrett - Imperial College London, UK
        - Professor B. M. Trost - Stanford University, USA
        - Professor H. N. C. Wong - Chinese University of Hong Kong, China

Submissions will be reviewed based upon originality, innovation, importance to the
field, applicability, rigor of approach and publication quality.

All submissions must include a PhD Supervisor letter of recommendation, a CV and a
representative peer-reviewed piece of published research. Entries should be submitted by
February 15, 2012 here: http://prize.reaxys.com

Reaxys(R) is a registered trademark owned and protected by Elsevier Properties SA and
used under license.

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for the
management of intellectual property. Elsevier Properties SA owns the PharmaPendium and
Reaxys(R) databases. Trademarks including Reaxys(R), PharmaPendium(TM) and The Lancet(R)
are owned and protected by Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include SciVerse ScienceDirect [http://www.sciencedirect.com ], SciVerse Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Nursing Consult [http://www.nursingconsult.com ], which
enhance the productivity of science and health professionals, and the SciVal suite
[http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which help
research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV; the combined market
capitalization of the two parent companies is approximately GBP12bn/EUR13bn. The ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York
Stock Exchange).

        Media contact
        Tom Reller
        Vice President of Global Relations, Elsevier

SOURCE Elsevier

Source: PR Newswire